Kyrgyzstan vs Turkmenistan: Prevalence rate of obesity in adults
Kyrgyzstan
22.0%
in 2024
Turkmenistan
22.2%
in 2024
Kyrgyzstan rank
106th
Turkmenistan rank
104th
Prevalence rate of obesity in adults over time
- Kyrgyzstan
- Turkmenistan
How they compare
Turkmenistan currently reports 22.2% against 22.0% in Kyrgyzstan, a difference of 0.2%.
The two have swapped places 1 time across 45 shared years of data; in 1980 it was Kyrgyzstan ahead.
Kyrgyzstan ranks 106th and Turkmenistan ranks 104th of 199 countries.
Turkmenistan has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Turkmenistan | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 8.1% | 8.3% | 0.2% | Turkmenistan |
| 1990s | 9.0% | 10.3% | 1.3% | Turkmenistan |
| 2000s | 11.2% | 13.5% | 2.3% | Turkmenistan |
| 2010s | 15.9% | 18.1% | 2.2% | Turkmenistan |
| 2020s | 20.7% | 21.4% | 0.7% | Turkmenistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of obesity in adults, Kyrgyzstan or Turkmenistan?
- Turkmenistan, at 22.2% against 22.0% in Kyrgyzstan as of 2024.
- What is the difference in prevalence rate of obesity in adults between Kyrgyzstan and Turkmenistan?
- 0.2%, with Turkmenistan ahead.
- How many years of comparable data are there for Kyrgyzstan and Turkmenistan?
- 45 years are reported by both, from 1980 to 2024.
- How do Kyrgyzstan and Turkmenistan rank globally for prevalence rate of obesity in adults?
- Kyrgyzstan ranks 106th and Turkmenistan ranks 104th of 199 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of obesity in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated prevalence of obesity in adults, based on general population surveys and statistical modeling. Obesity is a risk factor for chronic complications, including cardiovascular disease, and premature death.